Low tumor specificity and multidrug resistance (MDR) are two unmet issues for many anticancer drugs. In this talk, we will introduce a simple, effective strategy for concurrent tumor-targeted drug delivery and sensitization of resistant cancers to anticancer treatments using our newly developed matrix metalloproteinase 2 (MMP2)-sensitive self-assembling polymeric efflux inhibitor as a drug carrier. On several cancer models, including cancer cells, three-dimensional multicellular spheroids, and tumor-bearing mice, we demonstrated that the assembled MMP2-sensitive micelles could effectively carry and deliver various hydrophobic anticancer drugs to cancer cells. More important, the polymers/micelles could inhibit P-glycoprotein mediated drug efflux and sensitize the MDR cancers to anticancer therapeutics. Our in vitro and in vivo results suggested that the MMP2-sensitive polymers might have great potential to be a multifunctional nanocarrier for tumor-targeted drug delivery and therapy.

MMP2-sensitive tumor-targeted drug delivery and sensitization

2019 Spring National Meeting

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.